ACCELERATE MY DDR PROGRAM

Identifying stratification biomarkers beyond HRD could enable us to treat new patients of unmet need.
Turbine's answer

Simulations of complex cellular signaling networks to predict DDR inhibitor synthetic lethal opportunities marking patient with the highest chance to benefit

Finding right combinations and dosing regimens could help us overcome resistance, reduce toxicity and expand  the asset’s indication landscape.
Turbine's answer

Novel ideas for synergistic combination therapies across modalities

Understanding resistance would unlock long-term efficacy of our drug.
Turbine's answer

Drug assays in heterogeneous populations of cancer cell avatars with representation of alterations driving acquired resistance

BENEFITS ONLY TURBINE PROVIDES

Interpretable and causal simulation results with high specificity to molecular context and subtypes
Mechanically explained and ranked biomarker or synthetic lethality hypotheses with in vitro validation plans for top findings
Vast combination search space and heterogeneity inaccessible in vitro, speeding up findings and reducing trial-and-error
4
4 months from model calibration to delivery of mechanistic hypotheses
66348
Evaluated 66,348 combination-cell line pairs, (684 different drug combinations across 11 solid tumor indications)

    Close